FEops' technology transforms cardiac images into digital twins, virtual copies of the heart or its substructures. With this technology, the company aims to improve and expand personalized management for patients with structural heart disease.
The CE-marked and FDA-cleared FEops HEARTguide technology enables healthcare professionals to improve both procedure efficiency and clinical outcomes. It also empowers Medtech companies to bring superior products to the market faster than ever before.
- Invested amount
EUR 1 650 000
- Press Release
“This important milestone could only be reached by the continuous and high commitment from all our team members, the physicians who believe in our technology and other partners who support us in this journey. The EIC grant will not only boost our clinical and business implementation, but will also enable us to extend our device certifications.”
Matthieu De Beule, Co-founder & CEO